Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Daniel Y.C. Heng
Sign up to set email alerts
267
Publications
14,250
Citation Statements Received
5,805
Citation Statements Given
How they've been cited
19,427
516
13,654
80
How they cite others
7,389
228
5,541
36
Affiliations
University of Calgary
,
Arthur J.E. Child Comprehensive Cancer Centre
Publications
Order By: Most citations
Renal cell carcinoma
Hsieh
1
,
Purdue
2
,
Signoretti
3
et al.
2017
Nat Rev Dis Primers
Abstract
Show
3,112
15
2,316
3
Get access via publisher
Add to collection
Cite
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Heng
1
,
Xie
2
,
Regan
3
et al.
2009
JCO
Abstract
Show
2,191
41
1,625
6
Get access via publisher
Add to collection
Cite
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri
1
,
Escudier
2
,
Powles
3
et al.
2015
N Engl J Med
Abstract
Show
1,304
27
980
6
Get access via publisher
Add to collection
Cite
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Choueiri
1
,
Escudier
2
,
Powles
3
et al.
2016
The Lancet Oncology
Abstract
Show
979
45
824
9
Get access via publisher
Add to collection
Cite
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Heng
1
,
Xie
2
,
Regan
3
et al.
2013
The Lancet Oncology
Abstract
Show
1,055
20
733
6
Get access via publisher
Add to collection
Cite
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Motzer
1
,
Rini
2
,
McDermott
3
et al.
2019
The Lancet Oncology
847
27
666
6
5
Get access via publisher
Add to collection
Cite
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Heng
1
,
Wells
2
,
Rini
3
et al.
2014
European Urology
Abstract
Show
483
25
296
0
Get access via publisher
Add to collection
Cite
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hammers
1
,
Plimack
2
,
Infante
3
et al.
2017
JCO
Abstract
Show
534
11
284
0
Get access via publisher
Add to collection
Cite
1
2
3
4